Chiasma Reports First Quarter 2016 Results (Chiasma Inc)

Edit Public Technologies 11 May 2016
(Source. Chiasma Inc). WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc ... Marketing, G&A; Expenses ... Net Loss ... commercial launch of Mycapssa for adult patients with acromegaly, initiate a clinical trial of octreotide capsules supporting the potential treatment of patients with neuroendocrine tumors in late 2016, and advance its preclinical work to enable the company to announce a second product candidate by the end of 2016....

Better way to diagnose, manage neuroendocrine tumors

Edit Science Daily 10 May 2016
Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors (NETS), and could significantly impact treatment management, a new study suggests ... ....

Trovagene Announces First Quarter 2016 Financial Results (TrovaGene Inc)

Edit Public Technologies 10 May 2016
(Source. TrovaGene Inc). SAN DIEGO, May 10, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ ... First Quarter Financial Results ... Cash and Cash Equivalents ... Patient Case Report Published in Cancer Discovery Confirmation of BRAF V600E mutational status and quantitative monitoring of changes in urinary circulating tumor DNA (ctDNA) used to assess response to novel combination drug therapy for colorectal neuroendocrine tumors ... About Trovagene, Inc ... $....

A Better Way to Diagnose and Manage Neuroendocrine Tumors (SNMMI - Society of Nuclear Medicine and Molecular Imaging)

Edit Public Technologies 09 May 2016
(May 9, 2016) - A recent study reported in the May issue of The Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors (NETS), and could significantly impact treatment management ... Tumors' include....

Dicerna Reports First Quarter 2016 Financial and Operational Results (Dicerna Pharmaceuticals Inc)

Edit Public Technologies 09 May 2016
DCR-MYC is a potent and specific inhibitor of MYC, an oncogene frequently amplified or overexpressed in a wide variety of tumor types, including hepatocellular carcinoma (HCC) ... Phase 1 DCR-MYC Trial in Solid Tumors ... The first expansion cohort is enrolling patients with low-to-intermediate grade pancreatic neuroendocrine tumors (PNETs) having failed one or two lines of prior therapy....

Strongbridge Biopharma plc Announces Presentation at Bio€quity Europe 2016 (Strongbridge Biopharma plc)

Edit Public Technologies 05 May 2016
(Source. Strongbridge Biopharma plc) ... A. Brian Davis, chief financial officer of Strongbridge Biopharma, is scheduled to present on Wednesday, May 11 at 12.00 p.m. GMT ... Strongbridge's rare endocrine disease franchise also includes COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors ... Contacts ... (noodl....

Threshold Pharmaceuticals Reports First Quarter Financial Results (Threshold Pharmaceuticals Inc)

Edit Public Technologies 05 May 2016
Conducted additional analyses of evofosfamide data in pancreatic cancer; the Company intends to discuss potential registration pathways with health regulatory authorities; and Continued ongoing clinical development collaborations investigating evofosfamide in patients with pancreatic neuroendocrine tumors (pNET), recurrent glioblastoma (GBM) and hepatocellular carcinoma (HCC)....

Winship authored publications for April 2016 (The Winship Cancer Institute of Emory University)

Edit Public Technologies 04 May 2016
(Source. The Winship Cancer Institute of Emory University). Various first authors and senior authors from Winship Cancer Institute have published 62 studies in major medical and scientific journals in the past month ... Aquaporins. Their role in gastrointestinal malignancies ... Cancer letters ... PubMed PMID ... Surgical Management of Pancreatic Neuroendocrine Tumors ... RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis....

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2016 First Quarter Financial Results (Lexicon Pharmaceuticals Inc)

Edit Public Technologies 03 May 2016
(Source. Lexicon Pharmaceuticals Inc). Conference Call and Webcast at 10.00 a.m. Eastern Time. The Woodlands, Texas, May 3, 2016 - Lexicon Pharmaceuticals, Inc. (Nasdaq ... Excess production of serotonin within metastatic neuroendocrine tumor cells can lead to carcinoid syndrome, a condition characterized by serious consequences including frequent and debilitating diarrhea, facial flushing, abdominal pain, and heart valve damage ... Revenues....

BRIEF-Novartis says Afinitor gets nod in EU for some GI, lung neuroendocrine tumors

Edit Reuters 29 Apr 2016
* Novartis says afinitor recommended by chmp for european union approval to treat select gi and lung neuroendocrine tumors Source text for Eikon. Further company coverage. (Reporting By Zurich newsroom) ....

Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors (Novartis AG)

Edit Public Technologies 29 Apr 2016
Basel, April 29, 2016- Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Afinitor (everolimus) tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease....

Advanced Accelerator Applications reports 26.8% sales growth in 2015 and continues to show significant clinical progress across both therapeutic and diagnostic platforms – Company announces completed submission of Lutathera NDA and MAA to FDA and EMA respectively (Advanced Accelerator Applications SA)

Edit Public Technologies 29 Apr 2016
Presented favorable results of pivotal Phase III trial, NETTER-1, for Lutathera for the treatment of neuroendocrine tumors ... Lutathera (or 177Lu-DOTATATE) is a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs) ... tumors treated with Lutathera....

Advanced Accelerator Applications reports 26.8% sales growth in 2015 and continues to show significant clinical ...

Edit Stockhouse 29 Apr 2016
Lutathera (or 177Lu-DOTATATE) is a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs) ... objective response rate (”ORR”), and also suggests a survival benefit in patients with advanced midgut neuroendocrine tumors treated with Lutathera....
×